Cantor Fitzgerald Weighs in on NBIX FY2026 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings of $6.53 per share for the year. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The firm had revenue of $572.60 million for the quarter, compared to the consensus estimate of $587.06 million. During the same quarter in the prior year, the firm earned $1.20 earnings per share. The company’s revenue was up 11.1% on a year-over-year basis.

Several other equities analysts have also issued reports on NBIX. UBS Group boosted their price target on Neurocrine Biosciences from $137.00 to $152.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. Canaccord Genuity Group boosted their price target on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. BMO Capital Markets boosted their price target on Neurocrine Biosciences from $96.00 to $115.00 and gave the company a “market perform” rating in a research note on Tuesday, May 6th. Needham & Company LLC boosted their price target on Neurocrine Biosciences from $138.00 to $139.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. Finally, Guggenheim boosted their price target on Neurocrine Biosciences from $155.00 to $165.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $162.00.

Neurocrine Biosciences Stock Down 0.5%

Shares of NBIX opened at $124.17 on Tuesday. Neurocrine Biosciences has a 12-month low of $84.23 and a 12-month high of $157.98. The firm has a market capitalization of $12.29 billion, a price-to-earnings ratio of 37.74, a P/E/G ratio of 0.77 and a beta of 0.24. The stock’s 50-day moving average price is $111.18 and its 200 day moving average price is $121.93.

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $25,000. Geneos Wealth Management Inc. raised its position in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the last quarter. Huntington National Bank raised its position in shares of Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company’s stock worth $31,000 after acquiring an additional 97 shares during the last quarter. WPG Advisers LLC bought a new stake in shares of Neurocrine Biosciences during the first quarter worth $32,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Neurocrine Biosciences during the first quarter worth $34,000. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of Neurocrine Biosciences stock in a transaction on Monday, May 5th. The stock was sold at an average price of $110.20, for a total value of $3,306,000.00. Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at approximately $4,131,508.20. The trade was a 44.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kevin Charles Gorman sold 9,613 shares of the business’s stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total value of $1,157,212.94. Following the sale, the director now owns 514,596 shares of the company’s stock, valued at approximately $61,947,066.48. The trade was a 1.83% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

Neurocrine Biosciences announced that its board has authorized a share repurchase program on Friday, February 21st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.